The impact of GSTT2B and GSTT1 deletions and selected GSTT2 promoter SNPs [18] on the development of bladder cancer and the response of bladder cancer patients to BCG immunotherapy were determined. The gene discussed is GSTT2B; the disease is urinary bladder cancer.